Care Before Discrimination is a Human Right

Hundreds of thousands of patients in the Czech Republic, and potentially millions across the EU, use CBD and cannabis‑derived preparations to manage chronic pain, sleep disorders, anxiety, depression, and PTSD. On a Friday afternoon, May 29th, 2026, the Czech Government quietly sent a proposal to restrict CBD as a "drug precursor" into the internal interministerial comment procedure: a decision that would reach huge numbers of patients, shaped out of public view, on a notice the public cannot read, justified by an argument the evidence does not establish.
The INCB itself calls the precursor evidence "limited". CBD is not a controlled substance and is the active ingredient of an approved children's medicine (Epidyolex). The dangerous "spice"‑type synthetic cannabinoids are not made from CBD; the only real link is semi‑synthetic HHC — and HHC has itself been placed under international control (Schedule II, 1971 Convention, in force December 2025). Restricting CBD to prevent an HHC synthesis that is already controlled would be disproportionate. The EU's highest court has held that CBD is not a narcotic and that public‑health restrictions "cannot be based on purely hypothetical considerations" (CJEU, Kanavape, C‑663/18).
A covert restriction would not protect anyone. It would push patients to an unregulated black market with heavy metal, pesticide, and solvent contamination, while doing nothing about the synthetic cannabinoids it claims to target. We do not oppose regulation—we support quality standards, testing, labeling, and age limits. We oppose a hidden, disproportionate measure built on an unproven argument. Whatever one's view of CBD, a decision like this must be made in the open.
Sources: CJEU Kanavape (C‑663/18); INCB Precursors Report 2025; EUDA, semi‑synthetic cannabinoids; OHCHR, access to medicines as an element of the right to health; full appeal and references at cbdhumanright.org.